Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK study

Basit Öğe Kaydı
dc.authoridCanpolat, Ugur/0000-0002-4250-1706
dc.authoridAskin, Lutfu/0000-0001-7768-2562
dc.authoridSinan, Umit/0000-0002-4837-7099
dc.authoridUnlu, Serkan/0000-0001-6179-8579
dc.authorwosidCanpolat, Ugur/S-3482-2018
dc.authorwosidÜnlü, Serkan/AAA-3477-2020
dc.authorwosidAskin, Lutfu/H-1047-2018
dc.authorwosidSinan, Umit/A-7003-2017
dc.authorwosidPEHLIVANOGLU, SECKIN/ABC-9264-2021
dc.authorwosidaltay, servet/C-1387-2018
dc.authorwosidŞahin, Mahmut/JZD-7344-2024
dc.contributor.authorGedikli, Omer
dc.contributor.authorAltay, Servet
dc.contributor.authorUnlu, Serkan
dc.contributor.authorCakmak, Huseyin Altug
dc.contributor.authorAskin, Lutfu
dc.contributor.authorYanik, Ahmet
dc.contributor.authorBesli, Feyzullah
dc.date.accessioned2024-06-12T10:59:39Z
dc.date.available2024-06-12T10:59:39Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: This study aimed to evaluate the safety of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (NVAF) during daily clinical practice. Methods: This was a prospective study conducted between January 01, 2016, and April 01, 2017, in patients aged >= 18 years with a diagnosis of NVAF. We performed the study in 9 clinical centers from different regions of Turkey, and the mean follow-up period was 12+2 months. We investigated major and minor bleeding events of DOAC. Results: A total of 1807 patients with NVAF were enrolled. The mean age of the patients was 73.6 +/- 10.2 years, CHA2DS2-VASc score was 3.6 +/- 1.4, and HAS-BLED score was 2 +/- 1.2. The most frequently prescribed DOAC was dabigatran 110 mg bid in 409 (22.6%) patients. The patients on apixaban 2.5 mg bid were older (p<0.001). Patients on rivaroxaban 15 mg od also had a higher prevalence of chronic renal failure, 46 (16.7%) patients. A total of 205 (11.4%) bleeding events were observed; among these, 34 (1.9%) patients had major bleeding and 171 (9.4%) patients had minor bleeding. The major and minor bleeding events were 2/273 (0.7%) and 30/273 (10.9%) in patients receiving dabigatran 150 mg bid, 13/409 (3%) and 44/409 (10.7%) in patients receiving dabigatran 110 mg bid, 4/385 (1%) and 42/385 (10.9%) in patients receiving rivaroxaban 20 mg od, 8/276 (2.9%) and 27/276 (9.7%) in patients receiving rivaroxaban 15 mg od, 3/308 (0.9%) and 14/308 (4.5%) in patients receiving apixaban 5 mg bid, 4/156 (2.5%) and 14/156 (9%) in patients receiving apixaban 2.5 mg bid, respectively. The total bleeding events were 17 (5.6%) in patients receiving apixaban 5 mg, less than those receiving other DOACs. On multivariate analyses, rivaroxaban 20 mg od (p=0.002), ATRIA and HAS-BLED scores, and peripheral artery disease were independent indicators of bleeding. The most frequent location of major bleeding was the gastrointestinal system (GIS) [17 (0.9%) patients], and the most frequent location of minor bleeding was the gingiva [45 (2.5%) patients]. Conclusion: This study showed that similar results as the previous real-life study; however, we had some different results, such as the GIS tract bleeding was more frequent in patients receiving dabigatran 110 mg bid. The major and intracranial bleeding events were similar for different DOACs; and among DOACs, only rivaroxaban 20 mg od was associated with a high risk of bleeding.en_US
dc.identifier.doi10.5152/AnatolJCardiol.2021.57635
dc.identifier.endpage204en_US
dc.identifier.issn2149-2263
dc.identifier.issn2149-2271
dc.identifier.issue3en_US
dc.identifier.pmid33690135en_US
dc.identifier.scopus2-s2.0-85102797185en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage196en_US
dc.identifier.trdizinid508002en_US
dc.identifier.urihttps://doi.org/10.5152/AnatolJCardiol.2021.57635
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/508002
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20519
dc.identifier.volume25en_US
dc.identifier.wosWOS:000625084600012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Soc Cardiologyen_US
dc.relation.ispartofAnatolian Journal Of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDirect Oral Anticoagulantsen_US
dc.subjectMajor Bleedingen_US
dc.subjectMinor Bleedingen_US
dc.subjectReal-Life Dataen_US
dc.subjectNon-Valvular Atrial Fibrillationen_US
dc.subjectEuro Heart Surveyen_US
dc.subjectAtrial-Fibrillationen_US
dc.subjectWarfarinen_US
dc.subjectRisken_US
dc.subjectApixabanen_US
dc.subjectRivaroxabanen_US
dc.subjectManagementen_US
dc.subjectRegistryen_US
dc.subjectStrokeen_US
dc.titleReal-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu